article thumbnail

STAT+: Medicare paid substantially more for J&J’s Stelara when it was covered under Part D than under Part B

STAT

A popular biologic medicine used to combat autoimmune diseases cost Medicare and its beneficiaries considerably more when the injectable treatment was obtained at pharmacies rather than injected in physician offices due to different methods for determining payment, a new analysis found.

article thumbnail

STAT+: House panel takes first steps toward reining in hospitals with ‘site-neutral’ changes

STAT

WASHINGTON — A key House panel on Wednesday advanced several health care bills on Wednesday, including its first step toward a controversial effort to equalize Medicare payments between hospitals and physician offices.

Hospitals 251
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharmacist Salaries and Employment in 2023: The Grass Keeps Getting Greener in Hospitals

Drug Channels

Meanwhile, employment and salaries in non-retail settings—hospitals, physician offices, outpatient centers, and home healthcare—continued to grow. Find out during The 340B Drug Pricing Program: Trends, Controversies, and Outlook , a new live video webinar with Adam J. These settings now employ one in three U.S.

article thumbnail

Pharmacist Job Market in 2020: Hospital Employment Up, Retail Salaries Down

Drug Channels

What’s more, average base salaries for retail pharmacists have dropped, while salaries have risen for pharmacists employed by hospitals, physician offices, and other non-retail settings. . The 340B Drug pricing Program is a crucial topic for pharmacists.

article thumbnail

STAT+: Pharmalittle: How 98 days may cost J&J big bucks; Walgreens CEO departs

STAT

When Medicare this week announced the first 10 medicines that will be included in its brand-new drug price negotiation program, a J&J drug called Stelara that is used to treat Crohn’s disease was on the list. … Ninety-eight days may end up costing Johnson & Johnson , according to STAT.

article thumbnail

STAT+: Pharmalittle: Biden administration to fine drugmakers for price hikes on 27 meds; Dems push pharmacy chains over access to abortion pill

STAT

… The Biden administration will fine drugmakers that hiked prices faster than the inflation rate on 27 medicines administered in physician offices , STAT notes. Pfizer had the most drugs on the list of any manufacturer, with five. AbbVie’s blockbuster rheumatoid arthritis drug, Humira, is on the list.